Dennis C Coleman
Plumbers in Salt Lake City, UT

2002016, Oct 31, 2002

Feb 27, 2001

09/798027

Dennis Coleman - Salt Lake City UT, US

A61K009/20, A61K009/14

424/465000, 424/488000

Compositions and methods of manufacture for dissolvable and nondissolvable drug-containing dosage-forms for noninvasive administration of medicaments through mucosal tissues of the mouth, pharynx, and esophagus of a patient. The dosage-forms are particularly useful in the transmucosal delivery of central nervous system affecting drugs in a dose-to-effect manner such that a sufficient dose is administered to produce a desired effect. A dissolvable drug-containing dosage-form includes a binding agent that is formed into a solid matrix dissolvable in the mouth of the patient, and a pharmacologically effective dose of a central nervous system affecting drug dispersed throughout the matrix. A nondissolvable drug-containing dosage-form includes a drug containment matrix that is nondissolvable in the mouth of the patient, and a central nervous system affecting drug incorporated into the nondissolvable matrix. The dissolvable and nondissolvable drug-containing dosage-forms may include permeation enhancers capable of modifying the permeability of the mucosal tissues of the mouth, pharynx, and esophagus in order to facilitate transmucosal absorption of the drug.

4557724, Dec 10, 1985

Aug 12, 1983

6/522914

Donald E. Gregonis - Salt Lake City UT
Robert L. Stephen - Salt Lake City UT
Dennis L. Coleman - Salt Lake City UT
Stephen K. Hunter - Syracuse UT
Barry K. Hanover - Salt Lake City UT
Jeffrey J. Harrow - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT

A61M 2500

604 49

The present invention is directed to a subcutaneous peritoneal injection catheter apparatus and methods which minimizes catheter obstruction during use. The apparatus includes a receiving chamber or reservoir having a relatively small internal volume while employing a penetrable membrane and relatively enlarged target surface area. The reservoir is interconnected with the peritoneal cavity by a hollow stem. The penetrable membrane accommodates a hollow needle being inserted into the receiving reservoir and is configurated with a dome-like profile so that the membrane may also be depressed to expel insulin from the receiving reservoir into the peritoneal cavity in a direction generally toward the mesenteric peritoneal membrane. The portion of the apparatus which is in the peritoneal cavity is preferably constructed of, or coated with, a material which is capable of minimizing the adhesion of cells and the growth of bacteria on that portion of the apparatus. In a presently preferred embodiment of the subcutaneous peritoneal injection catheter, the portion of the catheter to be within the peritoneal cavity is constructed of a polyurethane material, and this polyurethane material is then coated with a solution of polyurethane and poly(ethylene glycol) in a suitable solvent.

4784486, Nov 15, 1988

Oct 6, 1987

7/106791

Richard A. Van Wagenen - Salt Lake City UT
Jeffrey D. Geisler - Salt Lake City UT
Donald E. Gregonis - Salt Lake City UT
Dennis L. Coleman - Salt Lake City UT

Albion Instruments - Salt Lake City UT

G01J 344, G01N 2165

356301

The concentration of multiple polyatomic gases are determined simultaneously by Raman light scattering. The gas sample is placed in a sampling cell and a polarized laser beam is passed through the cell, along a longitudinal axis. A portion of the light scattered by the gas sample is captured and detected by means of multiple collection optics-filter-detector channels. The scattered light exits the gas cell via windows located in the sides of the gas cell and enters the collection channels which are aligned with the cell windows. The cell windows are along the longitudinal axis of the laser beam and gas cell. Light scattered by the gas sample provides signals of both inelastic Raman scattered light and elastic laser scattered light which are directed to the collection channels. The optics of each channel transports the scattered light signals onto a laser line rejection filter where the elastic scattered laser signals are attenuated. The remaining inelastic Raman scattered signals are caused to be incident upon an interference filter which is specific to the transmission of one or more specific Raman lines.

5233996, Aug 10, 1993

Jan 24, 1991

7/647170

Dennis L. Coleman - Salt Lake City UT
Charles V. Owen - Highland UT
Noel de Nevers - Salt Lake City UT

BOC Health Care, Inc. - New Providence NJ

A61B 508, A67B 7105

128716

Described herein is a patient interfacing system for sampling the inspired and expired gases of a patient and removing moisture from the sample. In one embodiment of the present invention, a patient link receives the gases from the patient's airway circuit and a vaporization section vaporizes condensed moisture in the sample. A separator section allows the vaporized moisture component of the sample to exit the patient interfacing system before the gas sample reaches the monitoring instrument. A filter may also be utilized to prevent condensed moisture, particulates and liquids from entering the monitoring instrument. Thus, the patient interfacing system of the present invention provides a reliable, cost effective and efficient means for delivering gas samples to a monitoring instrument which reduces or prevents water condensation inside the gas analysis portion of the monitoring instrument.

2002010, Aug 8, 2002

Dec 10, 2001

10/013266

Dennis Coleman - Salt Lake City UT, US
Steven Shoemaker - Fort Myers FL, US

A61K009/70

424/468000

The present invention provides methods and drug formulations comprising a drug capable of conforming to a pharmacokinetic profile when administered to a patient's systemic circulation. The pharmacokinetic profile provides a pharmacodynamic profile having an optimal onset of effect, optimal duration of effect, and an optimal rate of offset of effect. The drug formulation has a carrier for administering the drug that provides user control over the rate of absorption in order to maintain the optimal pharmacokinetic profile and the optimal pharmacodynamic profile.